|
|
|
| ACTH |
200-250 pg/ml |
Jansson et al. Clin Endocrinol (Oxf) 1998 Feb;48(2):243-50 |
| Adiponectin (plasma) |
8.7~10.4 µg/ml (n=6) |
Phoenix Pharmaceuticals |
| Adiponectin (serum samples) |
11.82 ± 0.97 µg/ml [normal glucose tolerance (NGT)] |
Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9. |
| Adiponectin (serum samples) |
9.11 ± 1.12 µg/ml [impaired glucose tolerance(IGT)] |
Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9. |
| Adiponectin (serum samples) |
7.44 ± 1.53 µg/ml [diabetes (DM)] |
Nakanishi et al. Metabolism. 2005 Feb;54(2):194-9. |
| Adrenomedullin (AM) |
2.94 ± 0.15 fmol/mL; n = 16 |
Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3. |
| Adrenomedullin (AM) |
8.74 ± 0.44 fmol/mL; n = 16; class I or II of the New York Heart Association functional classification |
Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3. |
| Adrenomedullin (AM) |
11.82 ± 1.81 fmol/mL; n = 5; class III or IV of the New York Heart Association functional classification |
Kato et al. J Clin Endocrinol Metab. 1996 Jan;81(1):180-3. |
| Adrenomedullin (ADM) |
6.14 ±0.25 pmol/L |
Kato et al. Hypertens Res. 1999 Mar;22(1):61-5. |
| Adrenomedullin (ADM) |
480 ± 135 pg/ ml |
Pousset et al. Eur Heart J 2000 Jun;21(12):1009-14 |
| mADM (amidated mature form) |
0.5 ±0.1 fmol/ml |
Ishihara et al.Clin Nephrol 1999 Aug;52(2):119-23 |
| Intermedin/AM-2 |
50-120 pg/ml |
Phoenix Pharmaceuticals |
| Intermedin/AM-2, prepro (25-56) (Human) |
173 pg/ml |
Phoenix Pharmaceuticals |
| Amylin |
8.48±3.12 pmol/L (total plasma levels) |
Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7. |
| Amylin |
6.29±1.47 pmol/l (patients with type 2 diabetes) |
Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7. |
| Amylin |
3.33±0.46 pmol/l (patients with osteoporosis) |
Bronský et al. Osteoporos Int. 2004 Mar;15(3):243-7. |
| ANP (Fetal blood samples) |
ANP: 80.8±16.6 vs. 31.6±7.7 pg/ml |
Walther et al. Cardiovasc Res. 2001 Mar;49(4):817-9 |
| ANP |
24 fmol/ml |
Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6. |
| ANP |
73 pg/ml |
McDowell et al. Br J Clin Pharmacol 1997 Mar;43(3):329-32 |
| ANP |
27 ± 5 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| ANP (chronic cardiac failure) |
136 ± 35 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| NT-proANP |
1130 ±170 pmol/l |
Uusimaa et al. Int J Cardiol 1999 Apr 30;69(1):5-14 |
| Angiotensin II |
21 ±4 pg/ml |
Gustafsson et al. Blood Press 1992 May;1(1):50-6 |
| Apelin (apelin-12) |
175 pg/ml (by RIA) |
Boucher et al. Endocrinology. 2005 Apr;146(4):1764-71. |
| Apelin (apelin-12) |
275 pg/ml (obesity) |
Boucher et al. Endocrinology. 2005 Apr;146(4):1764-71. |
| Apelin (apelin-36) |
174±14 pg/ml |
Heinonen et al. Regul Pept. 2005 Aug 15;130(1-2):7-13 |
| Apelin (apelin-36) |
736 ± 50 pg/ml (obesity) |
Heinonen et al. Regul Pept. 2005 Aug 15;130(1-2):7-13 |
| Arg8-Vasopressin (AVP) |
0.9 ±0.2 pg/ml |
Pump et al. Am J Physiol 1999 Jul;277(1 Pt 2):R229-35 |
| BNP (Fetal blood samples) |
64.8+/-6.6 pg/ml |
Walther et al. Cardiovasc Res. 2001 Mar;49(4):817-9 |
| BNP |
17.5 ±1.6 pmol/L |
Sayama et al. Coron Artery Dis 1999 Oct;10(7):537-40 |
| BNP |
13.3 ±2.7 pg/ml |
Bando et al. Respir Med 1999 Jul;93(7):507-14 |
| BNP32 |
9.7 ±0.5 pmol/L |
Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96 |
| BNP32 |
29 ±2 pmol/L (NYHA Classes I, II and III ) |
Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96 |
| NT-proBNP |
1.5 (1.0 ~ 13.8) fmol/mL (women) |
Campbell et al. J Card Fail 2000 Jun;6(2):130-9 |
| NT-proBNP |
1.0 (1.0 ~ 3.3) fmol/mL (men) |
Campbell et al. J Card Fail 2000 Jun;6(2):130-9 |
| NT-proBNP |
10.8 ± 1.3 pmol/L |
Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96 |
| NT-proBNP |
129 ± 12 pmol/L (NYHA Classes I, II and III ) |
Hunt et al. Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96 |
| Bradykinin |
2.6 fmol/ml |
Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6. |
| Cholecystokinin (CCK) |
8.0 ± 6.3 pmol/l (control group) |
Foschi et al. Obes Surg. 2004 May;14(5):644-7 |
| Cholecystokinin (CCK) |
9.8 ±6.7 pmol/l [obese patients before vertical banded gastroplasty (VBG)] |
Foschi et al. Obes Surg. 2004 May;14(5):644-7 |
| Cholecystokinin (CCK) |
24.9 ±18 pmol/l [obese patients before vertical banded gastroplasty (VBG)] |
Foschi et al. Obes Surg. 2004 May;14(5):644-7 |
| CGRP |
13.9 (10.9-36.96) pmol/L |
Onuoha et al. Life Sci 1999;65(13): 1351-8 |
| CGRP |
34 pg/ml |
McDowell et al. Br J Clin Pharmacol 1997 Mar;43(3):329-32 |
| CGRP (external jugular vein blood levels) |
110 ±7 pmol/L (attacks of cluster headache) |
Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34 |
| CGRP (external jugular vein blood levels) |
less than 7 pmol/L (normal control) |
Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34 |
| Calcitonin |
6.9 pmol/L |
Henriksen et al. Metabolism 2000 Jan;49(1):47-52 |
| Calcitonin |
< 10 pg/mL |
Cohen et al. J Clin Endocrinol Metab 2000 Feb;85(2):919-22 |
| CNP-22 (Human) |
11.64 ±4.32 pg/ml |
Stepan et al. J Perinat Med 2000;28(2):118-21 |
| CNP |
7.1 ±2.5 pg ml (women with normal pregnancy) |
Stepan et al. Obstet Gynecol 1999; 93(2):199-202 |
| CNP |
7.36 ±3.0 pg/ml (Maternal Plasma in health pregnancy women in the third trimenon) |
Stepan et al. J Perinat Med 1998; 26(5):396-9 |
| CRF |
1.64 ±0.43 pmol/L( 0.77-2.5 pmol/L). |
Hashimoto et al. Acta Endocrinol (Copenh) 1993 Jun;128(6):503-7 |
| pro-alpha-C-related immunoreactive peptides (pro-alpha-C-RI) (serum) |
402 ±38 pg/mL |
Anawalt et al. J Clin Endocrinol Metab. 1996 Sep;81(9):3341-5. |
| DNP |
105.3 ±31.1 pg/mL |
Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5 |
| DNP |
235.6 ±45.8 pg/mL (pre-haemodialysis) |
Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5 |
| DNP |
204.4 ±55.4 pg/mL (after haemodialysis ) |
Lee et al. Nephrology (Carlton). 2004 Jun;9(3):171-5 |
| Endothelin |
8.8 (1.7-32.9) pmol/L |
Onuoha et al. Life Sci 1999;65(13): 1351-8 |
| Endorphin, Beta-, |
30 ±5 pg/ml |
Laurent et al. J Clin Endocrinol Metab. 2000 Jun;85(6):2170-5. |
| Endorphin, Beta-, |
18.9 ±5.4 pg/ ml (range 2.0 to 29.6 pg/ml), before treatment |
El-Sheikh et al. Pain Physician. 2004 Jan;7(1):67-70 |
| Endorphin, Beta-, |
38.7 ±17.6 pg/ml (range 13.2 to 67.9 pg/ml), after pain relief |
El-Sheikh et al. Pain Physician. 2004 Jan;7(1):67-70 |
| Gastrin |
7.8 ±1.6 pg/ml (before lunch) |
Takeyama et al. Chem Pharm Bull (Tokyo) 1993; 41(12):2197-9 |
| Gastrin |
26.4 ±8.4 pg/ml (after lunch) |
Takeyama et al. Chem Pharm Bull (Tokyo) 1993; 41(12):2197-9 |
| Gastrin I |
52.80 ±13.37 pg/ml (maternal blood) |
Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8 |
| Gastrin I |
84.12 ±42.90 pg/ml (cord blood) |
Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8 |
| Gastrin I |
32.34 ±18.35 pg/ml (plasma in healthy,nonpregnant women) |
Dokumov et al. Br. J. Obstet Gynaecol. 1981; 88(2):126-8 |
| Gastrin-relasing peptide (GRP) |
40 ± 4 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| Gastrin-relasing peptide (GRP) [(chronic cardiac failure)] |
29 ± 4 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| GH |
29.9±23.1 ng/ml |
Takeno et al. Eur J Endocrinol. 2004 Oct;151(4):447-50 |
| Ghrelin (Human) |
87.79 ±10.27 pg/ml |
Dr. C Y Bowers, School of Medicine, Tulane University Medical Center |
| GHRH (children with short stature) |
51 ± 10 pg/ml |
Brion et al. Horm Res. 1986;24(2-3):116-20. |
| GHRH (children with short stature) |
24.6 ± 4.9 pg/ml |
Rosskamp et al. Klin Wochenschr. 1988 Mar 15;66(6):257-60. |
| GHRH (children with Type 1 diabetes) |
27.0 ± 3.9 pg/ml |
Rosskamp et al. Klin Wochenschr. 1988 Mar 15;66(6):257-60. |
| GIP |
42 ±18 pmol/L |
Kruszynska et al. Hepatology 1995 Apr;21(4):933-41 |
| Glucagon |
57 ± 3 pg/ml (ng/L) |
Blümer et al. Metabolism. 2005 Jan;54(1):60-6. |
| GLP-1 [7-36 amide] |
16 ±1 pmol/L |
Kruszynska et al. Hepatology 1995 Apr;21(4):933-41 |
| GLP-1 |
0.25 pmol/L |
Gutzwiller et al. Am J Physiol 1999 May;276(5 Pt 2):R1541-4 |
| GLP-2 |
851 ±230 pg/ml |
Brubaker et al. Endocrinology. 1997 Nov;138(11):4837-43. |
| Insulin |
36 ± 3 pmol/L |
Blümer et al. Metabolism. 2005 Jan;54(1):60-6. |
| INSL3 (serum) |
758.42±83.21 pg/ml (male) |
Phoenix Pharmaceuticals |
| INSL3 (serum) |
59.42 ±25.76 pg/ml (female) |
Phoenix Pharmaceuticals |
| INSL3 (serum) |
566.3±163.5 pg/mL (male) |
Foresta et al. J Clin Endocrinol Metab. 2004 Dec;89(12):5952-8 |
| INSL3 (plasma) |
594.10±118.7 pg/ml (male) |
Phoenix Pharmaceuticals |
| INSL3 (plasma) |
47.13±19.84 pg/ml (female) |
Phoenix Pharmaceuticals |
| LL37 |
50-80 ng/ml |
Phoenix Pharmaceuticals |
| Leu-enkephalin |
5.22 ±1.53 pmol/ml |
Klin et al. Boll Chim Farm 1998 Sep;137(8):306-13 |
| MCH |
1.5 ng/ml |
Phoenix Pharmaceuticals |
| Motilin [migrating motor complex (MMC)] |
39 ± 6 pmol L-1 |
Naslund E, et al. Acta Physiol Scand. 1998 Nov;164(3):317-23 |
| Motilin |
64.1±30.1 pmol/L (healthy infants) |
Savino et al. Acta Paediatr. 2006 Jun;95(6):738-41 |
| NPY |
89.22 pg/ml |
Liu et al. Zhonghua Nei Ke Za Zhi. 1994 Oct;33(10):687-9. |
| NPY |
70.7 ± 5.9 pg/ml |
Kokot et al. Am J Nephrol 1999;19(1):28-33 |
| NPY |
11 (10.3-12.8) pmol/L |
Onuoha et al. Life Sci 1999;65(13): 1351-8 |
| NPY |
2.5 pmol/L |
Saelsen et al. Scand J Clin Lab Invest 1994 May;54(3):207-14 |
| NPY |
10.91 ±0.68 ng/ml |
Kokot et al. Arch Immunol Ther Exp (Warsz) 1998;46(5):311-6 |
| OFQ/nociceptin |
9.58 ± 2.57 pg/ml |
Ertsey et al. Cephalalgia. 2004 Apr;24(4):280-3 |
| OFQ/nociceptin |
4.91 ± 1.96 pg/ml ( cluster headache patients) |
Ertsey et al. Cephalalgia. 2004 Apr;24(4):280-3 |
| Orexin A |
20.6 ± 4.5 pg/ml |
Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9 |
| Orexin A (obstructive sleep apnea syndrome) |
9.4 ± 1.9 pg/ml |
Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9 |
| Orexin A (treated patients with OSAS) |
4.2 ± 1.5 pg/ml |
Busquets et al. Respiration. 2004 Nov-Dec;71(6):575-9 |
| Oxytocin |
1.3 ± 0.1 pmol/L (MW 1009.22) |
Ohlsson et al. BMC Gastroenterol. 2004 Oct 7;4:25. |
| Oxytocin |
1.66 ± 0.10 pmol/L (1.67+-0.10 pg/ml) [Early follicular] |
Altemus et al. J Clin Endocrinol Metab. 2001 Jun;86(6):2525-30. |
| Oxytocin |
1.95 ± 0.45 pmol/L (1.96 ± 0.45 pg/ml) [Midluteal] |
Altemus et al. J Clin Endocrinol Metab. 2001 Jun;86(6):2525-30. |
| Oxytocin |
[corpus cavernosum]66.7±34 to 75±44 pg/ml |
Uckert et al. World J Urol. 2003 May;20(6):323-6. |
| Oxytocin |
[cubital vein] 71±41 to 79±49.5 pg/ml |
Uckert et al. World J Urol. 2003 May;20(6):323-6. |
| Pancreatic Polypeptide |
218 ±23 pg/ml (healthy subjects) |
Glaser et al. Horm Metab res 1988; 20(5):288-92 |
| Pancreatic Polypeptide |
98 ±13 pg/ml (Obese with normal glucose tolerance) |
Glaser et al. Horm Metab res 1988; 20(5):288-92 |
| Pancreatic Polypeptide |
578 ±115 pg/ml (Obese with abnormal glucose tolerance) |
Glaser et al. Horm Metab res 1988; 20(5):288-92 |
| PYY (fasting levels) |
10.2±0.7 pmol/L (obese group) |
(Dr. Bloom's Lab) Batterham et al. N Engl J Med. 2003 Sep 4;349(10) : 941-8. |
| PYY (fasting levels) |
16.9±0.8 pmol/L (lean group) |
(Dr. Bloom's Lab) Batterham et al. N Engl J Med. 2003 Sep 4;349(10) : 941-8. |
| RBP-4 |
25.0 ± 8.9 mg/ml (n=10) |
Tan et al. J Clin Endocrinol Metab. 2007 Jul;92(7):2764-72. |
| RBP-4 (PCOS) |
35.0 ± 7.6 mg/ml (n=10) |
Tan et al. J Clin Endocrinol Metab. 2007 Jul;92(7):2764-72. |
| Resistin |
18.9 ± 3.4 ng/ml |
Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10. |
| Resistin (T2DM) |
22.6 ± 4.5 ng/ml |
Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10. |
| Resistin (CHD) |
24.2 ± 3.2 ng/ml |
Al-Daghri et al. Cardiovasc Diabetol. 2005 Jul 5;4(1):10. |
| Secretin |
6.7 ±0.5 pg/ml (fasting plasma) |
Rominger et al. Dig Dis Sci 1981; 26(7):591-7 |
| Secretin |
10.2 ±1.2 pg/ml (fasting plasma in duodenal ulcer ) |
Rominger et al. Dig Dis Sci 1981; 26(7):591-7 |
| Secretin |
32 ±4 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| Secretin [(chronic cardiac failure)] |
13± 1 ng/L (pg/ml) |
Nicholls et al. Eur Heart J. 1992 Oct;13(10):1399-404 |
| Somatostatin |
13.3 +/- 5.3 pg/ml |
Saito H, Saito S.Horm Metab Res. 1982 Feb;14(2):71-6. |
| Substance P |
<10 pg/mL |
Vinik et al. J Clin Endocrinol Metab. 1990 Jun;70(6):1702-9 |
| Substance P |
50 pg/mL as the cutoff point, the sensitivity was 63% for detection of a tumor, and 100% of nontumor patients were excluded |
Vinik et al. J Clin Endocrinol Metab. 1990 Jun;70(6):1702-9 |
| Substance P |
5.6 (3.2-36.6) pmol/L |
Onuoha et al. Life Sci 1999;65(13): 1351-8 |
| Substance P [ [[migrating motor complex (MMC)] |
718 ± 326 pmol L-1 |
Naslund et al. Acta Physiol Scand. 1998 Nov;164(3):317-23 |
| TNF-alpha |
21 pg/ml |
Cugno et al. Clin Sci (Lond). 2000 Nov;99(5):461-6. |
| TNF-alpha |
1.4 ± 0.3 pg/ml |
Blümer et al. Metabolism. 2005 Jan;54(1):60-6. |
| VIP |
9.8 pmol/L (0-34) |
Onuoha et al. Eur J Clin Invest. 2000 Jul;30(7):570-7 |
| VIP [[migrating motor complex (MMC)]] |
79 ± 23 pmol L-1 |
Naslund et al. Acta Physiol Scand. 1998 Nov;164(3):317-23 |
| VIP |
42.44 ± 2.540 pg/ml (range, 12.9-98.5 pg/ml) (serum) |
Hejna et al. Anticancer Res 2001 Mar-Apr;21(2A):1183-7 |
| VIP (external jugular vein blood) |
20 ± 3 pmol/L (attacks of cluster headache, normal less than 7 ) |
Goadsby et al. Brain. 1994 Jun;117 ( Pt 3):427-34 |
| VIP (by EIA) |
307.1±42.6 µg/ml |
Umemoto et al. J Dermatol Sci. 2003 Apr;31(2):161-4 |
| Urotensin II (Human) |
5.5 ±0.2 pg/ml (extracted plasma) |
Dr. Chao-Shu Tang, 1st Hospital, Peking University, P.R.China |
| Urotensin II (Human) |
45.5 ±3.1 pg/ml (non-extracted plasma) |
Dr. Chao-Shu Tang, 1st Hospital, Peking University, P.R.China |
| Urotensin II (Human) |
7.70 ±0.97 pg/ml (extracted plasma) |
Phoenix Pharmaceuticals |
| Urotensin II (Human) |
19.0 pg/mL [10.6-24.9 pg/mL] [CSF from patients with essential hypertension] |
Thompson et al. Anesth Analg. 2003 Nov;97(5):1501-3 |
| Urotensin II (Human) |
722.3 pg/mL [17.7-28.4 pg/mL] [CSF from patients with essential hypertension] |
Thompson et al. Anesth Analg. 2003 Nov;97(5):1501-3 |
| Urotensin II (Human) |
22.7 ± 6.1 pg/ml, n = 18, [sample from aortic root of patients with nonfailing hearts] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
38.2 ± 6.1 pg/ml, n = 21, [sample from pulmonary artery of patients with nonfailing hearts] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
230.9 ± 68.7 pg/ml, n = 21, [[sample from aortic root of CHF patients] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
142.1 ± 51.5 pg/ml, n = 10, [sample from aortic root of CHF patients with nonischemic cardiomyopathy] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
27.3 ± 12.4 pg/ml, n = 7 [sample from aortic root of patients with nonfailing hearts without coronary artery disease] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
311.6 ± 120.4 pg/ml, n = 11, [sample from aortic root of CHF patients with ischemic cardiomyopathy] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
19.8 ± 6.6 pg/ml, n = 11, [sample from aortic root of patients with nonfailing hearts and coronary artery disease] |
Russell et al. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81 |
| Urotensin II (Human) |
4.4 ±0.2 fmol/ml, n=10, [non-proteinuric diabetic patients] |
Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5 |
| Urotensin II (Human) |
7.8 ± 0.6 fmol/ml, n=6, [proteinuric diabetic patients] |
Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5 |
| Urotensin II (Human) |
7.3 ± 0.9 fmol/ml, n=22, [normal subjects] |
Totsune et al. Clin Sci (Lond). 2003 Jan;104(1):1-5 |
| Urotensin II (Human) |
8.8 ± 0.9 pmol/l [62 normotensive controls (45% male, aged 54 ± 13 years)] |
Cheung et al. J Hypertens. 2004 Jul;22(7):1341-4 |
| Urotensin II (Human) |
13.6 ± 1.4 pmol/l [Sixty-two hypertensive outpatient subjects (52% male, aged 57 ± 13 years)] |
Cheung et al. J Hypertens. 2004 Jul;22(7):1341-4 |
| Urotensin II (Human) |
3.70 ± 1.30 pg/ml |
Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5 |
| Urotensin II (Human) |
1.61 ± 1.02 pg/ml [Venous plasma, CHD patients ] |
Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5 |
| Urotensin II (Human) |
patients with stable angina (2.62±1.20 pg/ml), unstable angina (1.39±0.80 pg/ml) and acute myocardial infarction (AMI, 1.04±0.45 pg/ml, P=0.004) |
Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5 |
| Urotensin II (Human) |
patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) had higher U II levels than the other subjects in the CHD patient group (2.28±0.94 pg/ml vs 1.40±0.96 pg/ml, P=0.008), and the femoral plasma U II levels were significantly elevated after PTCT, increasing from 1.18±1.14 pg/ml to a postoperative level of 2.22±1.77 pg/ml (P=0.001). |
Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5 |
| Urotensin II (Human) |
patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA) had higher U II levels than the other subjects in the CHD patient group (2.28±0.94 pg/ml vs 1.40±0.96 pg/ml, P=0.008), and the femoral plasma U II levels were significantly elevated after PTCT, increasing from 1.18±1.14 pg/ml to a postoperative level of 2.22±1.77 pg/ml (P=0.001). |
Fang et al. Di Yi Jun Yi Da Xue Xue Bao. 2004 May;24(5):563-5 |
| Visfatin (obese subjects) |
37 ± 1 ng/ml |
Haider et al. J Clin Endocrinol Metab, 2006, 91(4): 1578-1581 |
